Description: Neurorepair Team (www.lin-bcn.com) at the Neurovascular Research laboratory (Vall d’Hebron Research institute, www.vhir.org, in Barcelona) is looking for a PostDoctoral Candidate to join the lab. during spring 2015. Our goal is to study both angiogenesis and neurogenesis in experimental and human studies to improve brain function and neurorecovery after stroke from a translational perspective. The candidate will participate in one project studying cellular and molecular markers of angiogenesis in a cohort of stroke patients under rehabilitation therapy, and posterior translation of the results into cellular and animal models. Also the collaboration with other projects of the lab. is expected.
.. (lire la suite)
Dr. Christian Stockmann, MD,
Paris- Cardiovascular Research Center - Inserm U970
Team 11 – Inflammatory vascular remodeling and microenvironmental homeostasis
56 rue Leblanc, 75015 Paris
Tel: 0033 1 53 98 80 11
e-mail : christian.stockmann@inserm.fr
The research team "Inflammatory vascular remodeling and microenvironmental homeostasis" is looking for a postdoctoral fellow to lead a research project on myeloid cell-driven angiogenesis during tumor relapse after chemotherapy using different mouse models of cancer. This postdoctoral position will be based in PARis Cardiovascular research Center. It will start as soon as possible and will be initially limited to 12 month with a possible extension. There is no nationality restriction. The working language will be French and/or English.
In the context of chemotherapeutic treatment, it is becoming increasingly recognized that the architecture of the tumor vasculature and its functionality, rather than blood vessel counts, determine the therapeutic outcome by controlling drug delivery as well as microenvironmental conditions. In most tumors, blood vessels significantly differ from normal vascular networks and are characterized by inefficient blood supply despite high vasculature density. Hence, a better understanding of mechanisms involved in the regulation of drug sensitivity is indispensable for improved cancer treatments. Vascular Endothelial Growth Factor (VEGF) is a major angiogenic factor and we have shown that deletion of VEGF in tumor infiltrating myeloid cells leads to improved functionality of intratumoral blood vessels, alleviated tumor hypoxia and increased susceptibility to cytotoxic agents in mouse models of cancer. However, most of the studies focus on the initial response of tumors to therapy, and preclinical studies on avoidance of tumor relapse are lacking... (lire la suite)
Comme tous les ans, la SCMC attribuera un prix d’une valeur de 1000 euros à une personne dont les travaux contribueront à développer les connaissances sur le cerveau et les maladies cérébrovasculaires.
Conditions de candidature :
- Avoir moins de 35 ans
- Etre membre de la SCMC, à jour de sa cotisation
- Thèse soutenue depuis moins de deux ans et au plus tard le 31/12/2013
(lire la suite)
University of Sheffield UK - Department of Neuroscience
Faculty: Faculty of Medicine, Dentistry and Health
Contract Type: Fixed-term for three years
Working Pattern: Full Time
Salary: Grade 7, £28,685 to £36,298 per annum with potential to progress to £39,649
Job Reference Number: UOS007813
We are seeking a highly motivated scientist to carry out research projects in Translational Cerebrovascular Disease. We are exploring innovative cerebroprotection strategies with the central purpose of developing novel clinical therapies for devastating vascular diseases of the brain. You will have an excellent research and publication track record and will contribute to the work of an internationally recognised research group. You must possess excellent organisation skills and the ability to interact well within a group. You should be qualified to PhD level (or equivalent) in Neuroscience or Biological Sciences and have experience and interest in translational research.
You will use in vivo and in vitro approaches to determine the molecular and cellular pathways that underlie preconditioning and cerebroprotection in the brain. We have already identified candidate pathways but these require further elucidation. After elucidation, pharmacological manipulation of the most ‘promising’ pathway would be the next step with the aim of developing a clinical therapy.
Expertise with cell culture (neuronal and astrocytic) and focal ischaemia models of stroke would be a considerable advantage
To apply for this role, please contact Professor Majid
Closing Date: 9 October 2013
Professor Arshad Majid majidarshad@msn.com Professor of Cerebrovascular Neurology
Sheffield Institute for Translational Neuroscience (SITraN)
University of Sheffield
385A Glossop Road
SHEFFIELD S10 2HQ
